Phase 2 N=17 Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
Medullary Thyroid Cancer (MTC)
Primary: Clinical Response — 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=17 Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
Medullary Thyroid Carcinoma · Multiple Endocrine Neoplasia Type 2A · Multiple Endocrine Neoplasia Type 2B
Primary: Maximum Tolerated Dose (MTD) — 100 mg/m^2/day
Phase 3 N=330 Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
Thyroid Cancer
Primary: Progression-Free Survival (PFS) — 11.2; 4.0 months
Phase 3 N=331 An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
Thyroid Cancer
Primary: Progression-Free Survival(PFS) — 30.5; 19.2 Months
Phase 2 N=19 A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Thyroid Cancer
Primary: Objective Response Rate (ORR) — 3 Participants
Phase 2 N=35 QUILT-3.006 for Recurrent Medullary Thyroid Cancer
Medullary Thyroid Cancer (MTC)
Primary: Calcitonin Growth Rate — -2.53; -2.49 days^-1 — p=0.3760
Phase 2 N=13 Trial of LBH589 in Metastatic Thyroid Cancer
Thyroid Carcinoma
Primary: Tumor Response Rate to LBH589. — 13; 0 participants
Phase 2 N=21 Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
Hereditary Thyroid Gland Medullary Carcinoma · Locally Advanced Thyroid Gland Medullary Carcinoma · Multiple Endocrine Neoplasia Type 2A
Primary: Objective Response Rate of Sorafenib Tosylate in Metastatic Medullary Thyroid Carcinoma in Setting of Inherited Tumor Syndromes as Well as in Setting of Sporadic…
Phase 2 N=3 A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
Anaplastic Thyroid Cancer · Thyroid Cancer · Differentiated Thyroid Cancer
Primary: Maximum Tolerated Dose (MTD) [Phase I Dose Escalation] — 5 mg
Phase 2 N=117 Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology
Thyroid Cancer
Primary: Objective Response Rate (ORR) — 50.0; 35.6 Percentage of participants
Phase 2 N=42 Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
Thyroid Cancer
Primary: Number of Participants With Response Per Responsive Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) — 17; 9; 11 Participants
Phase 2 N=30 Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
Thyroid Cancer
Primary: Objective Response Rate — 6 Participants
Phase 2 N=50 RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Thyroid Cancer
Primary: Median Progression Free Survival — 12.5 months
Phase 2 N=14 Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma
Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma
Primary: Objective Response Rate Within the First 56 Weeks After the First Dose of Vandetanib — 38.5 percentage of participants
Phase 2 N=50 A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
Pheochromocytoma · Paraganglioma
Primary: Number of Patients With Complete (CR), Partial (PR), or Minor (MR) Response and Without Progressive Disease — 28 Participants
Phase 2 N=590 Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
RET-altered Non Small Cell Lung Cancer · Medullary Thyroid Cancer · RET-altered Papillary Thyroid Cancer
Primary: Phase 1 : Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Pralsetinib — 400; 400 mg
Phase 4 N=81 To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
Thyroid Cancer
Primary: Overall Response Rate (ORR) for Vandetanib 150 and 300mg With Responses Determined by the Investigator — 0.20; 0.29 Proportion of participants
Phase 2 N=23 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
Papillary Thyroid Cancer · Follicular Thyroid Cancer · Differentiated Thyroid Cancer
Primary: Progression Free Survival — 241 days
N/A N=4 Anti-3-[18F]FACBC Imaging of Parathyroid Adenomas
Parathyroid Disease
Primary: Detection Rate of Parathyroid Adenomas of Anti-3-[18F]FACBC Modality — 80 percentage of adenomas detected
Phase 2 N=28 Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Neuroendocrine Tumors · Metastatic Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 13; 12 participants
Phase 2 N=60 Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer
Thyroid Neoplasms
Primary: Percentage of Participants With Objective Response (OR) — 38.3 Percentage of participants
Phase 2 N=63 Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer
Thyroid Cancer
Primary: PET-CT Fusion Scanning Sensitivity — 49; 54 percentage of participants
N/A N=10 Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436
Papillary Thyroid Carcinoma
Primary: Increased Radioiodine Uptake — 6 Participants
Phase 2 N=6 Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
Anaplastic Thyroid Cancer
Primary: Overall Response (OR) — 0; 3; 3; 1 Participants
Phase 2 N=73 RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
Advanced and Metastatic Silent Neuro-Endocrine Tumors · Carcinoma · Neuroendocrine
Primary: Percentage of Participants' Best Overall Response Rate at 12 Months - Per Protocol Set (PP) — 0.0; 0.0; 56.7; 43.3 percentage of participants
N/A N=12 Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study
Papillary Carcinoma of Thyroid Gland · Metastatic Medullary Thyroid Cancer · Follicular Thyroid Cancer Lymph Node Metastasis
Primary: Primary Efficacy Parameters of Sensitivity of High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles (LSN MRI) — 85.5 percentage…
Phase 2 N=35 Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
Recurrent Thyroid Cancer · Stage IVA Follicular Thyroid Cancer · Stage IVA Papillary Thyroid Cancer
Primary: Overall Response Rate — 11 Participants
Phase 2 N=39 Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine
Recurrent Thyroid Gland Carcinoma · Stage I Thyroid Gland Papillary Carcinoma · Stage II Thyroid Gland Papillary Carcinoma
Primary: Objective Response Rate (ORR) — 1 Participants
Phase 4 N=50 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
NeuroEndocrine Tumours
Primary: Assessment of Clinical Symptomatic Response — 77.8; 95.5; 87.5; 22.2 Percentage of Subjects — p==0.126
Phase 2 N=27 Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer
Thyroid Cancer
Primary: Percentage of Participants With Local-regional Progression-free Survival — 15.2 percentage of all participants